Letters
Rosiglitazone saga
Authors’ reply
BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d2573 (Published 21 April 2011) Cite this as: BMJ 2011;342:d2573
- Yoon Kong Loke, senior lecturer in clinical pharmacology1,
- Chun Shing Kwok, medical student1,
- Sonal Singh, assistant professor of medicine2
- 1School of Medicine, Health Policy and Practice, University of East Anglia, Norwich NR4 7TJ, UK
- 2Johns Hopkins University School of Medicine, Baltimore, MD, USA
- y.loke{at}uea.ac.uk
Heazlewood describes the modest evidence for pioglitazone’s beneficial effect on a composite cardiovascular end point but fails to mention the inconclusive data on individual end points, such as myocardial infarction (relative risk 0.81, 95% confidence interval 0.64 to 1.02; P=0.08) or death (0.92, 0.76 to 1.11; P=0.38) compared with non-thiazolidinedione …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.